Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcus Biosciences (RCUS) Non Operating Income (2017 - 2025)

Arcus Biosciences has reported Non Operating Income over the past 9 years, most recently at $8.0 million for Q4 2025.

  • Quarterly results put Non Operating Income at $8.0 million for Q4 2025, down 20.0% from a year ago — trailing twelve months through Dec 2025 was $33.0 million (down 31.25% YoY), and the annual figure for FY2025 was $33.0 million, down 31.25%.
  • Non Operating Income for Q4 2025 was $8.0 million at Arcus Biosciences, up from $7.0 million in the prior quarter.
  • Over the last five years, Non Operating Income for RCUS hit a ceiling of $13.0 million in Q2 2024 and a floor of $154000.0 in Q1 2021.
  • Median Non Operating Income over the past 5 years was $8.0 million (2023), compared with a mean of $6.8 million.
  • Biggest five-year swings in Non Operating Income: plummeted 76.2% in 2021 and later surged 4088.48% in 2023.
  • Arcus Biosciences' Non Operating Income stood at $519000.0 in 2021, then surged by 1248.75% to $7.0 million in 2022, then soared by 57.14% to $11.0 million in 2023, then fell by 9.09% to $10.0 million in 2024, then decreased by 20.0% to $8.0 million in 2025.
  • The last three reported values for Non Operating Income were $8.0 million (Q4 2025), $7.0 million (Q3 2025), and $8.0 million (Q2 2025) per Business Quant data.